Learn the common signs of mental illness in adults and adolescents.
Learn more about common mental health conditions that affect millions
Find Your Local NAMI
Call the NAMI Helpline at
Or in a crisis, text "NAMI" to 741741
Generic name: buprenorphine (byoo pre NOR feen)
All FDA black box warnings are at the end of this fact sheet. Please review before taking this medication.
Medication assisted treatment (MAT) is the use of medications in combination with counseling and behavioral therapies for the treatment of substance use disorders. A combination of medication and behavioral therapies is effective in the treatment of substance use disorders and can help some people to sustain recovery.
Buprenorphine (Probuphine®, Sublocade®, and Subutex®) is a medication that works in the brain to treat opioid use disorder. Opioids include heroin and prescription pain relievers such as hydrocodone, oxycodone, morphine, and fentanyl. Certain formulations of buprenorphine (such as Belbuca®, Buprenex®, and Butrans®) are FDA approved to treat moderate to severe acute and chronic pain but not opioid use disorder.
Buprenorphine is known as a partial opioid agonist which means it partially works like an opioid and the effect is weaker than full agonists like heroin and methadone. It also has a “ceiling effect” so the opioid effects level off even with further dose increases which reduces the risk of misuse, dependency, and side effects. Buprenorphine lowers the effects of opioid withdrawal symptoms and cravings to use opioids without having full opioid potency or effects. This helps people who take the medication abstain from other opioids. It is important to combine buprenorphine treatment with counseling and other support.
Symptoms of opioid use disorder include:
Your healthcare provider will determine when buprenorphine should be started. If it is started too early after using other opioids, you could experience withdrawal symptoms, such as sweating, shaking, nausea, vomiting, diarrhea, body aches, anxiety, irritability, or runny nose.
Do not stop taking buprenorphine, even when you feel better. With input from you, your health care provider will assess how long you will need to take the medicine. If buprenorphine is stopped abruptly, you may have withdrawal symptoms.
Missing doses of buprenorphine may increase your risk for relapse.
Respiratory depression (slowed breathing) and death can rarely happen when buprenorphine is taken as prescribed. This risk is increased when buprenorphine is injected into the body or when it is mixed with other depressants including benzodiazepine medications (such as lorazepam, diazepam, or alprazolam) and alcohol. Patients taking buprenorphine or their caregivers should seek immediate medical attention if they start to experience unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficulty breathing, or unresponsiveness.
Do not inject (“shoot-up”) buprenorphine. This can cause uncomfortable withdrawal symptoms, respiratory depression (slowed breathing), or death in someone dependent on opioids.
There have been deaths reported in people who have never used opioids before after using low doses of buprenorphine.
Buprenorphine is not recommended in people with severe liver disease. Liver injury is rare. This can be monitored through blood tests. Alert your doctor immediately if you experience any yellowing of your skin and/or eyes, severe stomach pain, or severe nausea or vomiting.
Tell all of your providers and pharmacists that you are on buprenorphine. You should not take other medications with buprenorphine without talking to your provider.
Do not drive or operate heavy machinery until you know how you will respond to buprenorphine.
Store buprenorphine out of the reach and sight of children. Buprenorphine can cause serious respiratory depression (slowed breathing) and death in children.
If you are planning on becoming pregnant, notify your healthcare provider to best manage your medications. People living with substance use disorders that wish to become pregnant face important decisions and challenges. Active substance use disorders during pregnancy put the fetus at great risk. It is important to discuss the risks and benefits of continued treatment with your doctor and caregivers.
Opioid use disorder in pregnancy is associated with adverse outcomes such as low birth weight, preterm birth, and fetal death. Receiving treatment for opioid use disorder during pregnancy lower these risks.
The effects of buprenorphine on the fetus when used in pregnant women are unknown. Buprenorphine did not appear to cause structural abnormalities during animal studies. There was evidence of obstructed labor, fetal death, neonatal death, and developmental delays in animal studies. These results cannot be applied to humans. Buprenorphine did not show an increased risk of major structural abnormalities when studied in pregnant women. Opioid withdrawal symptoms may occur in newborn infants of women who were taking buprenorphine during pregnancy. There have been reports of poor feeding, diarrhea, irritability, tremor, trouble breathing, low heart rate, rigidity, and seizure in infants exposed to buprenorphine.
Methadone is better studied for pregnant women needing medication for opioid use disorder. Buprenorphine without naloxone is a reasonable alternative to methadone for pregnant women. Buprenorphine/naloxone should only be used in pregnancy if the benefits outweigh the risk to the fetus.
Regarding breastfeeding, caution is advised since buprenorphine does pass into breast milk. Small studies of buprenorphine use in breastfeeding women did not show adverse events in breastfed infants. When used for pain, the manufacturer does not recommend breast feeding. When used for opioid addiction the manufacturer recommends caution be used. Nursing mothers who are taking buprenorphine should monitor their infants for signs of increased drowsiness or trouble breathing.
The buprenorphine formulations that are used for opioid dependence are the sublingual tablet, subdermal implant, or subcutaneous injection. The combination product buprenorphine/naloxone (Suboxone) is the preferred therapy over buprenorphine alone for opioid dependence.
On the first day of buprenorphine treatment, a starting dose for the tablet of up to 8mg is usually recommended. This starting dose should be carefully adjusted under the supervision of a certified health care provider to find the safest and most effective dose for you. The recommended daily maintenance dose of buprenorphine tablets is usually 16mg taken once per day. Buprenorphine tablets should be dissolved under the tongue. Do not swallow. Keep the tablets in place under the tongue until completely dissolved. Do not eat or drink anything until the tablets are completely dissolved. If more than one tablet is needed to reach the prescribed dose, place all tablets in different places under the tongue at the same time. If this is not possible, see the detailed instructions on the medication guide that came with your prescription or ask your health care provider.
The buprenorphine implant (Probuphine®) requires insertion of 4 implants under the skin in the inner upper arm. Removal is completed at 6 months after insertion. If therapy is continued, then 4 new implants are placed in the opposite arm for 6 months. Treatment is to be discontinued after one insertion in each arm. Only your healthcare provider can determine the correct dosage form or dose.
Buprenorphine subcutaneous injections (Sublocade®) should be administered monthly with a minimum of 26 days between doses. Patient should be initiated on transmucosal buprenorphine for a minimum of 7 days before starting the subcutaneous injection.
Your provider or pharmacist can show you how to take buprenorphine. You can find detailed instructions on how to use buprenorphine tablets in the medication guide that comes with your prescription from the pharmacy.
Consider using a calendar, pillbox, alarm clock, or cell phone alert to help you remember to take your medication. You may also ask a family member or a friend to remind you or check in with you to be sure you are taking your medication.
If you miss a dose of oral buprenorphine, take it as soon as you remember unless it is closer to the time of your next dose. Do not double your next dose or take more than what is prescribed.
Avoid drinking alcohol, using sedatives, or other opioid pain medications (such as codeine, hydrocodone, oxycodone, or morphine), or using illegal drugs while you are taking buprenorphine. They may increase adverse effects (e.g., sedation, overdose, death) of the medication. Keep in mind that some cough syrups may contain opioid pain medication. Discuss all medications with your doctor and pharmacist prior to taking buprenorphine.
If an overdose occurs, call your doctor or 911. You may need urgent medical care. You may also contact the poison control center at 1-800-222-1222.
Evzio® (naloxone) injection or Narcan® (naloxone) nasal spray is a medication that can be used to reverse overdose from opioids including buprenorphine/naloxone. You should always call 911 after giving someone naloxone to treat an overdose. Ask your provider if naloxone is right for you.
Common side effects
Rare/serious side effects
Buprenorphine is a partial opioid agonist. Like other opioids, buprenorphine causes physical dependency when taken daily for a long period of time. This means that you may have withdrawal symptoms if buprenorphine is stopped abruptly. Withdrawal symptoms when stopping buprenorphine are usually not as severe as with other full opioids. Talk to your provider before stopping buprenorphine.
There have been reports of respiratory depression (slowed breathing) and death in patients taking buprenorphine with benzodiazepine medications such as alprazolam (Xanax®), clonazepam (Klonopin®), diazepam (Valium®), lorazepam (Ativan®), and temazepam (Restoril®). These medications should be taken exactly as prescribed. It is very dangerous to take buprenorphine with benzodiazepines if you do not have a prescription.
The following medications may increase the effects of buprenorphine:
The following medications may decrease the effects of buprenorphine:
Buprenorphine will begin working shortly after taking one dose.
This medication has an opiate drug in it. The FDA has found that the use of opiate drugs with benzodiazepine drugs or other sedating medications can result in serious adverse reactions including slowed or difficult breathing and death. Benzodiazepine drugs include drugs like alprazolam, clonazepam, and lorazepam. Benzodiazepine drugs are used to treat health problems like anxiety, trouble sleeping, or seizures. Patients taking opioids with benzodiazepines, other sedating medications, or alcohol, and caregivers of these patients, should seek immediate medical attention if they start to experience unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficulty breathing, or unresponsiveness. Buprenorphine implants and subcutaneous injections are only available through restricted programs (Sublocade REMS and Probuphine REMS). Buprenorphine subcutaneous injections should only be administered by a healthcare provider as serious harm or death could result if administered intravenously. Insertion and removal of buprenorphine implants are associated with the risk of implant migration, protrusion, expulsion, and nerve damage resulting from the procedure.
©2020 The College of Psychiatric and Neurologic Pharmacists (CPNP). CPNP makes this document available under the Creative Commons Attribution-No Derivatives 4.0 International License. Last Updated: January 2016.
This information is being provided as a community outreach effort of the College of Psychiatric and Neurologic Pharmacists. This information is for educational and informational purposes only and is not medical advice. This information contains a summary of important points and is not an exhaustive review of information about the medication. Always seek the advice of a physician or other qualified medical professional with any questions you may have regarding medications or medical conditions. Never delay seeking professional medical advice or disregard medical professional advice as a result of any information provided herein. The College of Psychiatric and Neurologic Pharmacists disclaims any and all liability alleged as a result of the information provided herein.
Call the NAMI Helpline at
text "NAMI" to 741741